This page has only limited features, please log in for full access.
Aims To study if machine learning methodology can be used to detect persons with increased type 2 diabetes or prediabetes risk among people without known abnormal glucose regulation. Methods Machine learning and interpretable machine learning models were applied on research data from Stockholm Diabetes Preventive Program, including more than 8000 people initially with normal glucose tolerance or prediabetes to determine high and low risk features for further impairment in glucose tolerance at follow-up 10 and 20 years later. Results The features with the highest importance on the outcome were body mass index, waist-hip ratio, age, systolic and diastolic blood pressure, and diabetes heredity. High values of these features as well as diabetes heredity conferred increased risk of type 2 diabetes. . The machine learning model was used to generate individual, comprehensible risk profiles, where the diabetes risk was obtained for each person in the data set. Features with the largest increasing or decreasing effects on the risk were determined. Conclusions The primary application of this machine learning model is to predict individual type 2 diabetes risk in people without diagnosed diabetes, and to which features the risk relates However, since most features affecting diabetes risk also play a role for metabolic control in diabetes, e.g. body mass index, diet composition, tobacco use, and stress, the tool can possibly also be used in diabetes care to develop more individualized, easily accessible health care plans to be utilized when encountering the patients.
Lara Lama; Oskar Wilhelmsson; Erik Norlander; Lars Gustafsson; Anton Lager; Per Tynelius; Lars Wärvik; Claes-Göran Östenson. Machine learning for prediction of diabetes risk in middle-aged Swedish people. Heliyon 2021, 7, 1 .
AMA StyleLara Lama, Oskar Wilhelmsson, Erik Norlander, Lars Gustafsson, Anton Lager, Per Tynelius, Lars Wärvik, Claes-Göran Östenson. Machine learning for prediction of diabetes risk in middle-aged Swedish people. Heliyon. 2021; 7 (7):1.
Chicago/Turabian StyleLara Lama; Oskar Wilhelmsson; Erik Norlander; Lars Gustafsson; Anton Lager; Per Tynelius; Lars Wärvik; Claes-Göran Östenson. 2021. "Machine learning for prediction of diabetes risk in middle-aged Swedish people." Heliyon 7, no. 7: 1.
Chronic care management is dependent on productive interactions between patients and healthcare professionals. Digital health technologies (eHealth) open up new possibilities for improving the quality of care, but there is a limited understanding of what productive interactions entail. This study explores characteristics of productive interactions to support self-care and healthcare in the context of eHealth use in diabetes care. We collected qualitative data based on interviews with nurses and responses to open-ended survey questions from patients, prior to and post using an eHealth service for self-monitoring and digital communication. We found that eHealth’s influence on productive interactions was characterized by unconstrained access, health parameter surveillance, and data-driven feedback, with implications for self-care and healthcare. Our findings indicate that eHealth perforates the boundaries that define interactions under traditional, non-digital care. This was manifested in expressions of uncertainty and in blurred boundaries between self-care and healthcare. We conclude that the attainment of a sustainable eHealth ecosystem will require healthcare to acknowledge eHealth as a disruptive change that may require re-organization to optimally support the productive use of eHealth services for both patients and staff, which includes agreement on new routines, as well as social interaction rules.
Carolina Wannheden; Ulrica Von Thiele Schwarz; Claes-Göran Östenson; Karin Pukk Härenstam; Terese Stenfors. What’s the Name of the Game? The Impact of eHealth on Productive Interactions in Chronic Care Management. Sustainability 2021, 13, 5221 .
AMA StyleCarolina Wannheden, Ulrica Von Thiele Schwarz, Claes-Göran Östenson, Karin Pukk Härenstam, Terese Stenfors. What’s the Name of the Game? The Impact of eHealth on Productive Interactions in Chronic Care Management. Sustainability. 2021; 13 (9):5221.
Chicago/Turabian StyleCarolina Wannheden; Ulrica Von Thiele Schwarz; Claes-Göran Östenson; Karin Pukk Härenstam; Terese Stenfors. 2021. "What’s the Name of the Game? The Impact of eHealth on Productive Interactions in Chronic Care Management." Sustainability 13, no. 9: 5221.
Aims/hypothesis Chronic stimulation of β2-adrenoceptors, opposite to acute treatment, was reported to reduce blood glucose levels, as well as to improve glucose and insulin tolerance in rodent models of diabetes by essentially unknown mechanisms. We recently described a novel pathway that mediates glucose uptake in skeletal muscle cells via stimulation of β2-adrenoceptors. In the current study we further explored the potential therapeutic relevance of β2-adrenoceptor stimulation to improve glucose homeostasis and the mechanisms responsible for the effect. Methods C57Bl/6N mice with diet-induced obesity were treated both acutely and for up to 42 days with a wide range of clenbuterol dosages and treatment durations. Glucose homeostasis was assessed by glucose tolerance test. We also measured in vivo glucose uptake in skeletal muscle, insulin sensitivity by insulin tolerance test, plasma insulin levels, hepatic lipids and glycogen. Results Consistent with previous findings, acute clenbuterol administration increased blood glucose and insulin levels. However, already after 4 days of treatment, beneficial effects of clenbuterol were manifested in glucose homeostasis (32% improvement of glucose tolerance after 4 days of treatment, p < 0.01) and these effects persisted up to 42 days of treatment. These favourable metabolic effects could be achieved with doses as low as 0.025 mg kg−1 day−1 (40 times lower than previously studied). Mechanistically, these effects were not due to increased insulin levels, but clenbuterol enhanced glucose uptake in skeletal muscle in vivo both acutely in lean mice (by 64%, p < 0.001) as well as during chronic treatment in diet-induced obese mice (by 74%, p < 0.001). Notably, prolonged treatment with low-dose clenbuterol improved whole-body insulin sensitivity (glucose disposal rate after insulin injection increased up to 1.38 ± 0.31%/min in comparison with 0.15 ± 0.36%/min in control mice, p < 0.05) and drastically reduced hepatic steatosis (by 40%, p < 0.01) and glycogen (by 23%, p < 0.05). Conclusions/interpretation Clenbuterol improved glucose tolerance after 4 days of treatment and these effects were maintained for up to 42 days. Effects were achieved with doses in a clinically relevant microgram range. Mechanistically, prolonged treatment with a low dose of clenbuterol improved glucose homeostasis in insulin resistant mice, most likely by stimulating glucose uptake in skeletal muscle and improving whole-body insulin sensitivity as well as by reducing hepatic lipids and glycogen. We conclude that selective β2-adrenergic agonists might be an attractive potential treatment for type 2 diabetes. This remains to be confirmed in humans.
Anastasia Kalinovich; Nodi Dehvari; Alice Åslund; Sten Van Beek; Carina Halleskog; Jessica Olsen; Elisabete Forsberg; Evelyn Zacharewicz; Gert Schaart; Mia Rinde; Anna Sandström; Roger Berlin; Claes-Göran Östenson; Joris Hoeks; Tore Bengtsson. Treatment with a β-2-adrenoceptor agonist stimulates glucose uptake in skeletal muscle and improves glucose homeostasis, insulin resistance and hepatic steatosis in mice with diet-induced obesity. Diabetologia 2020, 63, 1603 -1615.
AMA StyleAnastasia Kalinovich, Nodi Dehvari, Alice Åslund, Sten Van Beek, Carina Halleskog, Jessica Olsen, Elisabete Forsberg, Evelyn Zacharewicz, Gert Schaart, Mia Rinde, Anna Sandström, Roger Berlin, Claes-Göran Östenson, Joris Hoeks, Tore Bengtsson. Treatment with a β-2-adrenoceptor agonist stimulates glucose uptake in skeletal muscle and improves glucose homeostasis, insulin resistance and hepatic steatosis in mice with diet-induced obesity. Diabetologia. 2020; 63 (8):1603-1615.
Chicago/Turabian StyleAnastasia Kalinovich; Nodi Dehvari; Alice Åslund; Sten Van Beek; Carina Halleskog; Jessica Olsen; Elisabete Forsberg; Evelyn Zacharewicz; Gert Schaart; Mia Rinde; Anna Sandström; Roger Berlin; Claes-Göran Östenson; Joris Hoeks; Tore Bengtsson. 2020. "Treatment with a β-2-adrenoceptor agonist stimulates glucose uptake in skeletal muscle and improves glucose homeostasis, insulin resistance and hepatic steatosis in mice with diet-induced obesity." Diabetologia 63, no. 8: 1603-1615.
SNAP23 is the ubiquitous SNAP25 isoform that mediates secretion in non-neuronal cells, similar to SNAP25 in neurons. However, some secretory cells like pancreatic islet β cells contain an abundance of both SNAP25 and SNAP23, where SNAP23 is believed to play a redundant role to SNAP25. We show that SNAP23, when depleted in mouse β cells in vivo and human β cells (normal and type 2 diabetes [T2D] patients) in vitro, paradoxically increased biphasic glucose-stimulated insulin secretion corresponding to increased exocytosis of predocked and newcomer insulin granules. Such effects on T2D Goto-Kakizaki rats improved glucose homeostasis that was superior to conventional treatment with sulfonylurea glybenclamide. SNAP23, although fusion competent in slower secretory cells, in the context of β cells acts as a weak partial fusion agonist or inhibitory SNARE. Here, SNAP23 depletion promotes SNAP25 to bind calcium channels more quickly and longer where granule fusion occurs to increase exocytosis efficiency. β Cell SNAP23 antagonism is a strategy to treat diabetes.
Tao Liang; Tairan Qin; Fei Kang; Youhou Kang; Li Xie; Dan Zhu; Subhankar Dolai; Dafna Greitzer-Antes; Robert K. Baker; Daorong Feng; Eva Tuduri; Claes-Goran Ostenson; Timothy J. Kieffer; Kate Banks; Jeffrey E. Pessin; Herbert Y. Gaisano. SNAP23 depletion enables more SNAP25/calcium channel excitosome formation to increase insulin exocytosis in type 2 diabetes. JCI Insight 2020, 5, 1 .
AMA StyleTao Liang, Tairan Qin, Fei Kang, Youhou Kang, Li Xie, Dan Zhu, Subhankar Dolai, Dafna Greitzer-Antes, Robert K. Baker, Daorong Feng, Eva Tuduri, Claes-Goran Ostenson, Timothy J. Kieffer, Kate Banks, Jeffrey E. Pessin, Herbert Y. Gaisano. SNAP23 depletion enables more SNAP25/calcium channel excitosome formation to increase insulin exocytosis in type 2 diabetes. JCI Insight. 2020; 5 (3):1.
Chicago/Turabian StyleTao Liang; Tairan Qin; Fei Kang; Youhou Kang; Li Xie; Dan Zhu; Subhankar Dolai; Dafna Greitzer-Antes; Robert K. Baker; Daorong Feng; Eva Tuduri; Claes-Goran Ostenson; Timothy J. Kieffer; Kate Banks; Jeffrey E. Pessin; Herbert Y. Gaisano. 2020. "SNAP23 depletion enables more SNAP25/calcium channel excitosome formation to increase insulin exocytosis in type 2 diabetes." JCI Insight 5, no. 3: 1.
ObjectiveThe first aim was to determine the extent of the relationship between place of birth and self-rated health (SRH) in primary healthcare patients born outside Sweden and those born in Sweden. The second aim was to investigate whether socioeconomic and lifestyle factors explained any differences.SettingTwo academic primary healthcare centres in Stockholm County, Sweden.Participants825 patients at high risk of developing pre-diabetes and diabetes, aged 18–74 years, attending academic healthcare centres in areas with large numbers of immigrants, 56.8% born abroad and 43.2% born in Sweden. Patients with a diagnosis of diabetes were excluded. Inclusion criteria were based on previous research showing that people born in Middle Eastern and Asian countries who live in Sweden have a high prevalence of and risk for diabetes.OutcomeSRH was dichotomised as optimal (very good/good) and suboptimal (fair/bad/very bad) and compared in those born outside Sweden and in Sweden.ResultsThere was a statistically significant difference in the SRH of the two groups (p=0.008). Logistic regression analysis showed a crude OR for reduced SRH of 1.46 (95% CI 1.10 to 1.92) in patients born outside Sweden. After controlling for education, employment and marital status, the OR increased to 1.50 (95% CI 1.11 to 2.02). After controlling for physical activity and smoking, it decreased to 1.36 (95% CI 1.00 to 1.85).ConclusionSocioeconomic and lifestyle factors influenced SRH. It could therefore be useful for clinicians to consider these factors when providing care for patients born outside Sweden and resettled in areas with large numbers of immigrants.
Marina Taloyan; Amina Amri; Kristin Hjörleifsdottir Steiner; Fahimeh Lamian; Claes-Goran Ostenson; Helena Salminen. Extent of the association between self-rated health and place of birth: a cross-sectional study among people at high risk of developing pre-diabetes and diabetes in Sweden. BMJ Open 2019, 9, e028757 .
AMA StyleMarina Taloyan, Amina Amri, Kristin Hjörleifsdottir Steiner, Fahimeh Lamian, Claes-Goran Ostenson, Helena Salminen. Extent of the association between self-rated health and place of birth: a cross-sectional study among people at high risk of developing pre-diabetes and diabetes in Sweden. BMJ Open. 2019; 9 (12):e028757.
Chicago/Turabian StyleMarina Taloyan; Amina Amri; Kristin Hjörleifsdottir Steiner; Fahimeh Lamian; Claes-Goran Ostenson; Helena Salminen. 2019. "Extent of the association between self-rated health and place of birth: a cross-sectional study among people at high risk of developing pre-diabetes and diabetes in Sweden." BMJ Open 9, no. 12: e028757.
Diabetes risk can be controlled and even reversed by making dietary changes. The aim of this study was to improve the understanding of how older persons with a high risk of developing Type 2 diabetes manage and relate to information about diabetes risk over a ten-year period. Fifteen qualitative interviews were conducted among participants from the Stockholm Diabetes Prevention Program (SDPP). The participants were asked to recall the health examinations conducted by the SDPP related to their prediabetes and to describe their experiences and potential changes related to diet and physical activity. Data were analyzed using qualitative content analysis. The main theme found was that T2D (type 2 diabetes) risk is not perceived as concrete enough to motivate lifestyle modifications, such as changing dietary patterns, without other external triggers. Diagnosis was recognized as a reason to modify diet, and social interactions were found to be important for managing behavior change. Diagnosis was also a contributing factor to lifestyle modification, while prognosis of risk was not associated with efforts to change habits. The results from this study suggest that the potential of reversing prediabetes needs to be highlighted and more clearly defined for older persons to serve as motivators for lifestyle modification.
Linda Timm; Meena Daivadanam; Anton Lager; Birger Forsberg; Claes-Göran Östenson; Helle Mölsted Alvesson. “I Did Not Believe You Could Get Better”—Reversal of Diabetes Risk Through Dietary Changes in Older Persons with Prediabetes in Region Stockholm. Nutrients 2019, 11, 2658 .
AMA StyleLinda Timm, Meena Daivadanam, Anton Lager, Birger Forsberg, Claes-Göran Östenson, Helle Mölsted Alvesson. “I Did Not Believe You Could Get Better”—Reversal of Diabetes Risk Through Dietary Changes in Older Persons with Prediabetes in Region Stockholm. Nutrients. 2019; 11 (11):2658.
Chicago/Turabian StyleLinda Timm; Meena Daivadanam; Anton Lager; Birger Forsberg; Claes-Göran Östenson; Helle Mölsted Alvesson. 2019. "“I Did Not Believe You Could Get Better”—Reversal of Diabetes Risk Through Dietary Changes in Older Persons with Prediabetes in Region Stockholm." Nutrients 11, no. 11: 2658.
Mobile health, mHealth is recognized as a strategy to improve lifestyle behaviors. Research targeting specific lifestyle behaviors has shown that interventions using smartphones can be effective. However, few studies have evaluated solutions with multicomponent interventions, tailoring the intervention to the specific needs of the participant using a combination of mHealth and conventional treatment. To accomplish this, we developed Health Integrator, an mHealth platform with services and offers in the areas of diet, physical activity, sleeping habits, stress, alcohol and tobacco use. In the system, the user selects an area of intervention together with a health coach and set weekly goals. This study protocol presents the design and methodology of the Health Integrator Study, a randomized controlled trial to promote improved lifestyle behaviors. A three-arm parallel randomized controlled trial (1:1:1) is conducted in the Stockholm County, Sweden. In total, 209 employees at a four different companies representing both white and blue collar workers, have been recruited. Participants are randomized to either a control group or to one of two intervention groups receiving a 3-month lifestyle behavior change program including either 1) use of Health Integrator and monthly health coaching sessions or 2) only Health Integrator. At baseline and follow-up after 3- and 6-months, all participants answer questionnaires assessing lifestyle behaviors and quality of life. At baseline and the 3-month follow-up (end of intervention period), weight, height, waist circumference and blood pressure are measured, and all participants wear an Actigraph accelerometer for 7 days to assess physical activity. Blood lipid profile and HbA1c are measured among all participants at baseline. If baseline measures fall outside the normal range, a second measurement is done after 3 months. The Health Integrator Intervention Study will evaluate if a personalized intervention combining mHealth and conventional programs for lifestyle change, with or without additional health coach sessions, can improve lifestyle behaviors and quality of life. Based on the results from this trial, Health Integrator can easily be implemented within a broad public. ClinicalTrials.gov Identifier: NCT03579342. Retrospectively registered, first submitted May 8, 2018.
Stephanie E. Bonn; Marie Löf; Claes-Göran Östenson; Ylva Trolle Lagerros. App-technology to improve lifestyle behaviors among working adults - the Health Integrator study, a randomized controlled trial. BMC Public Health 2019, 19, 273 .
AMA StyleStephanie E. Bonn, Marie Löf, Claes-Göran Östenson, Ylva Trolle Lagerros. App-technology to improve lifestyle behaviors among working adults - the Health Integrator study, a randomized controlled trial. BMC Public Health. 2019; 19 (1):273.
Chicago/Turabian StyleStephanie E. Bonn; Marie Löf; Claes-Göran Östenson; Ylva Trolle Lagerros. 2019. "App-technology to improve lifestyle behaviors among working adults - the Health Integrator study, a randomized controlled trial." BMC Public Health 19, no. 1: 273.
The global prevalence of type 2 diabetes is increasing rapidly; consequently there is great need for new and novel therapeutic options. Gynostemma pentaphyllum (GP) is a traditional medicinal plant, mainly present in Southeast Asian countries, that has been reported to exert antidiabetic effects, by stimulating insulin secretion. The specific compound responsible for this effect is however as yet unidentified. Screening for discovery and identification of bioactive compounds of an herbal GP extract, was performed in isolated pancreatic islets from spontaneously diabetic Goto-Kakizaki (GK) rats, a model of type 2 diabetes, and from non-diabetic control Wistar rats. From this herbal extract 27 dammarane-type saponins, including two novel compounds, were isolated and their structure was elucidated by mass spectrometry and NMR spectroscopy. One of the dammarane-type triterpenoid showed a glucose-dependent insulin secretion activity. This compound, gylongiposide I, displays unique abilities to stimulate insulin release at high glucose levels (16.7 mM), but limited effects at a low glucose concentration (3.3 mM). Further studies on this compound, also in vivo, are warranted with the aim of developing a novel anti-diabetic therapeutic with glucose-dependent insulinogenic effect.
Lena C. E. Lundqvist; Darren Rattigan; Emad Ehtesham; Camila Demmou; Claes-Göran Östenson; Corine Sandström. Profiling and activity screening of Dammarane-type triterpen saponins from Gynostemma pentaphyllum with glucose-dependent insulin secretory activity. Scientific Reports 2019, 9, 1 -10.
AMA StyleLena C. E. Lundqvist, Darren Rattigan, Emad Ehtesham, Camila Demmou, Claes-Göran Östenson, Corine Sandström. Profiling and activity screening of Dammarane-type triterpen saponins from Gynostemma pentaphyllum with glucose-dependent insulin secretory activity. Scientific Reports. 2019; 9 (1):1-10.
Chicago/Turabian StyleLena C. E. Lundqvist; Darren Rattigan; Emad Ehtesham; Camila Demmou; Claes-Göran Östenson; Corine Sandström. 2019. "Profiling and activity screening of Dammarane-type triterpen saponins from Gynostemma pentaphyllum with glucose-dependent insulin secretory activity." Scientific Reports 9, no. 1: 1-10.
Effective prevention and care for type 2 diabetes requires that people link healthy behaviours to chronic disease-related wellbeing. This study explored how people perceive current and future wellbeing, so as to inform lifestyle education. Eight focus group discussions and 12 in-depth interviews were conducted in Iganga and Mayuge districts in rural Eastern Uganda among people aged 35–60 years in three risk categories (1) People with diabetes, (2) people at higher risk of diabetes (with hypertension or overweight) and (3) community members without diabetes. People define wellbeing in three notions: 1) Physical health, 2) Socio-economic status and 3) Aspirational fulfilment. Most people hold the narrower view of wellbeing that focuses on absence of pain. Most overweight participants did not feel their condition as affecting their wellbeing. However, for several people with hypertension, the pains they describe indicate probable serious heart disease. Some people with diabetes expressed deep worry and loss of hope, saying that ‘thoughts are more bothersome than the illness’. Wellbeing among people with diabetes was described in two perspectives: Those who view diabetes as a ‘static’ condition think that they cannot attain wellbeing while those who view it as a ‘dynamic’ condition think that with consistent treatment and healthy lifestyles, they can be well. While many participants perceive future wellbeing as important, people without diabetes are less concerned about it than those with diabetes. Inadequate knowledge about diabetes, drug stock-outs in health facilities, unaffordable healthier food, and contradictory information were cited as barriers to future wellbeing in people with diabetes. To make type 2 diabetes prevention relevant to healthy people, health education messages should link current lifestyles to future wellbeing. Diabetes patients need counselling support, akin to that in HIV care, to address deep worry and loss of hope.
R. W. Mayega; E. Ekirapa; B. Kirunda; C. Nalwadda; J. Aweko; G. Tomson; C. G. Ostenson; J. Van Olmen; M. Daivadanam; J. Kiguli. ‘What kind of life is this?’ Diabetes related notions of wellbeing among adults in eastern Uganda and implications for mitigating future chronic disease risk. BMC Public Health 2018, 18, 1 -13.
AMA StyleR. W. Mayega, E. Ekirapa, B. Kirunda, C. Nalwadda, J. Aweko, G. Tomson, C. G. Ostenson, J. Van Olmen, M. Daivadanam, J. Kiguli. ‘What kind of life is this?’ Diabetes related notions of wellbeing among adults in eastern Uganda and implications for mitigating future chronic disease risk. BMC Public Health. 2018; 18 (1):1-13.
Chicago/Turabian StyleR. W. Mayega; E. Ekirapa; B. Kirunda; C. Nalwadda; J. Aweko; G. Tomson; C. G. Ostenson; J. Van Olmen; M. Daivadanam; J. Kiguli. 2018. "‘What kind of life is this?’ Diabetes related notions of wellbeing among adults in eastern Uganda and implications for mitigating future chronic disease risk." BMC Public Health 18, no. 1: 1-13.
Purinergic signaling may be altered in diabetes accounting for endothelial dysfunction. Uridine adenosine tetraphosphate (Up4A), a novel dinucleotide substance, regulates vascular function via both purinergic P1 and P2 receptors (PR). Up4A enhances vascular contraction in isolated arteries of diabetic rats likely through P2R. However, the precise involvement of PRs in endothelial dysfunction and the vasoconstrictor response to Up4A in diabetes has not been fully elucidated. We tested whether inhibition of PRs improved endothelial function and attenuated Up4A-mediated vascular contraction using both aortas and mesenteric arteries of type 2 diabetic (T2D) Goto Kakizaki (GK) rats vs. control Wistar (WT) rats. Endothelium-dependent (EDR) but not endothelium-independent relaxation was significantly impaired in both aortas and mesenteric arteries from GK vs. WT rats. Non-selective inhibition of P1R or P2R significantly improved EDR in aortas but not mesenteric arteries from GK rats. Inhibition of A1R, P2X7R, or P2Y6R significantly improved EDR in aortas. Vasoconstrictor response to Up4A was enhanced in aortas but not mesenteric arteries of GK vs. WT rats via involvement of A1R and P2X7R but not P2Y6R. Depletion of major endothelial component nitric oxide enhanced Up4A-induced aortic contraction to a similar extent between WT and GK rats. No significant differences in protein levels of A1R, P2X7R, and P2Y6R in aortas from GK and WT rats were observed. These data suggest that altered PR sensitivity accounts for endothelial dysfunction in aortas in diabetes. Modulating PRs may represent a potential therapy for improving endothelial function.
Ali Mahdi; Tong Jiao; Yahor Tratsiakovich; Jiangning Yang; Claes-Göran Östenson; John Pernow; Zhichao Zhou. Altered Purinergic Receptor Sensitivity in Type 2 Diabetes-Associated Endothelial Dysfunction and Up4A-Mediated Vascular Contraction. International Journal of Molecular Sciences 2018, 19, 3942 .
AMA StyleAli Mahdi, Tong Jiao, Yahor Tratsiakovich, Jiangning Yang, Claes-Göran Östenson, John Pernow, Zhichao Zhou. Altered Purinergic Receptor Sensitivity in Type 2 Diabetes-Associated Endothelial Dysfunction and Up4A-Mediated Vascular Contraction. International Journal of Molecular Sciences. 2018; 19 (12):3942.
Chicago/Turabian StyleAli Mahdi; Tong Jiao; Yahor Tratsiakovich; Jiangning Yang; Claes-Göran Östenson; John Pernow; Zhichao Zhou. 2018. "Altered Purinergic Receptor Sensitivity in Type 2 Diabetes-Associated Endothelial Dysfunction and Up4A-Mediated Vascular Contraction." International Journal of Molecular Sciences 19, no. 12: 3942.
Studies comparing provider and patient views and experiences of self-management within primary healthcare are particularly scarce in disadvantaged settings. In this qualitative study, patient and provider perceptions of self-management were investigated in five socio-economically disadvantaged communities in Stockholm. Twelve individual interviews and four group interviews were conducted. Semi-structured interview guides included questions on perceptions of diabetes diagnosis, diabetes care services available at primary health care centers, patient and provider interactions, and self-management support. Data was analyzed using thematic analysis. Two overarching themes were identified: adopting and maintaining new routines through practical and appropriate lifestyle choices (patients), and balancing expectations and pre-conceptions of self-management (providers). The themes were characterized by inherent dilemmas representing confusions and conflicts that patients and providers experienced in their daily life or practice. Patients found it difficult to tailor information and lifestyle advice to fit their daily life. Healthcare providers recognized that patients needed support to change behavior, but saw themselves as inadequately equipped to deal with the different cultural and social aspects of self-management. This study highlights patient and provider dilemmas that influence the interaction and collaboration between patients and providers and hinder uptake of self-management advice.
Juliet Aweko; Jeroen De Man; Pilvikki Absetz; Claes-Göran Östenson; Stefan Swartling Peterson; Helle Mölsted Alvesson; Meena Daivadanam. Patient and Provider Dilemmas of Type 2 Diabetes Self-Management: A Qualitative Study in Socioeconomically Disadvantaged Communities in Stockholm. International Journal of Environmental Research and Public Health 2018, 15, 1810 .
AMA StyleJuliet Aweko, Jeroen De Man, Pilvikki Absetz, Claes-Göran Östenson, Stefan Swartling Peterson, Helle Mölsted Alvesson, Meena Daivadanam. Patient and Provider Dilemmas of Type 2 Diabetes Self-Management: A Qualitative Study in Socioeconomically Disadvantaged Communities in Stockholm. International Journal of Environmental Research and Public Health. 2018; 15 (9):1810.
Chicago/Turabian StyleJuliet Aweko; Jeroen De Man; Pilvikki Absetz; Claes-Göran Östenson; Stefan Swartling Peterson; Helle Mölsted Alvesson; Meena Daivadanam. 2018. "Patient and Provider Dilemmas of Type 2 Diabetes Self-Management: A Qualitative Study in Socioeconomically Disadvantaged Communities in Stockholm." International Journal of Environmental Research and Public Health 15, no. 9: 1810.
Lupinus mutabilis (LM) is a legume part of Bolivian traditional diet that has a nutraceutical property reducing blood glucose levels. The prevalence of type 2 diabetes is increasing worldwide thus; the search for novel anti-diabetic drugs is needed. Based on its traditional use, we evaluated the anti-diabetic effect of LM in the spontaneously diabetic Goto-Kakizaki (GK) rat, a model of type 2 diabetes and in Wistar (W) rats as healthy control. LM seeds hydroethanolic extract, analyzed by gas chromatography-mass spectrometry and high-performance liquid chromatography-high resolution mass spectrometry, is a complex mixture of volatile and non-volatile components. A single oral administration of LM extract (2000 mg/kg b.w.) improved glucose tolerance during the oral glucose tolerance test (OGTT) (30–120 min) in GK and W rats (p < 0.0001). The long-term treatment with LM (1000 mg/kg b.w.), for 21 days, improved the area under the curve (AUC) of glucose during OGTT at day 20, in both GK (p < 0.01) and W rats (p < 0.01). The HbA1c (GK rats, p < 0.05 and W rats, p < 0.0001) and the non-fasting glucose (GK rats, p < 0.05) were also reduced. LM increased both serum insulin levels (2.4-fold in GK rats and 2.5-fold W rats), and the glucose-induced (16.7 mM glucose) insulin release in isolated islets from treated animals (6.7-fold in GK rats, and 6.6-fold in W rats). Moreover, LM (10 mg/mL) stimulated in vitro glucose induced (16.7 mM glucose) insulin release in batch incubated GK and W rat islets (p < 0.0001). In perifused GK rat islets, insulin release in 16.7 mM glucose was increased 95.3-fold compared to untreated islets (p < 0.0001), while no significant differences were found in perifused W rat islets. The LM mechanism of action, evaluated using inhibitory compounds of the insulin secretion pathway, showed that LM-dependent insulin secretion was reduced 42% by diazoxide (p < 0.001), 70% by nifedipine (p < 0.001), 86.7% by H89 (p < 0.0001), 70.8% by calphostine-C (p < 0.0001) and 93% by pertussis toxin (p < 0.0001). A similar effect was observed in W rats islets. Our findings provide evidence that LM has an anti-diabetic effect through stimulation of insulin release. The effect is-dependent on L-type calcium channel, protein kinase A and C systems, and G protein-coupled exocytosis and is partially mediated by K-ATP channels.
Silvia Zambrana; Lena C. E. Lundqvist; Orlando Mamani; Sergiu-Bogdan Catrina; Eduardo Gonzales; Claes-Göran Östenson. Lupinus mutabilis Extract Exerts an Anti-Diabetic Effect by Improving Insulin Release in Type 2 Diabetic Goto-Kakizaki Rats. Nutrients 2018, 10, 933 .
AMA StyleSilvia Zambrana, Lena C. E. Lundqvist, Orlando Mamani, Sergiu-Bogdan Catrina, Eduardo Gonzales, Claes-Göran Östenson. Lupinus mutabilis Extract Exerts an Anti-Diabetic Effect by Improving Insulin Release in Type 2 Diabetic Goto-Kakizaki Rats. Nutrients. 2018; 10 (7):933.
Chicago/Turabian StyleSilvia Zambrana; Lena C. E. Lundqvist; Orlando Mamani; Sergiu-Bogdan Catrina; Eduardo Gonzales; Claes-Göran Östenson. 2018. "Lupinus mutabilis Extract Exerts an Anti-Diabetic Effect by Improving Insulin Release in Type 2 Diabetic Goto-Kakizaki Rats." Nutrients 10, no. 7: 933.
Amaranthus caudatus is traditionally used to treat infections. Based on its traditional usage, we investigated the effect of A. caudatus on the bladder epithelial cells in the protection of E. coli infection. The direct antimicrobial effects of A. caudatus on uropathogenic bacteria were investigated using minimum inhibitory concentration (MIC) assay. Bladder epithelial cell lines T24 and 5637 and uropathogenic E. coli strain #12 were used to investigate the effect of A. caudatus. Bacterial adhesion and invasion into bladder cells treated with A. caudatus was analyzed. Expression of uroplakin-1a (UPK1A), β1 integrin (ITGB1), caveolin-1 (CAV1) and the antimicrobial peptides human β defensin-2 (DEFB4A) and LL-37 (CAMP) was evaluated using RT-PCR. No direct antibacterial effect on E. coli or any of the tested uropathogenic strains was observed by A. caudatus. However, we demonstrated reduced mRNA expression of uroplakin-1a and caveolin-1, but not β1 integrin after treatment of uroepithelial cells, mirrored by the decreased adhesion and invasion of E. coli. A. caudatus treatment did not induce increased gene expression of the antimicrobial peptides, LL-37 and human β-defensin-2. Our results showed that A. caudatus has a protective role on bladder epithelial cells against uropathogenic E. coli infection by decreasing the bacterial adhesion and invasion, thereby preventing infection.
Soumitra Mohanty; Silvia Zambrana; Soizic Dieulouard; Witchuda Kamolvit; Vera Nilsén; Eduardo Gonzales; Claes-Göran Östenson; Annelie Brauner. Amaranthus caudatus extract inhibits the invasion of E. coli into uroepithelial cells. Journal of Ethnopharmacology 2018, 220, 155 -158.
AMA StyleSoumitra Mohanty, Silvia Zambrana, Soizic Dieulouard, Witchuda Kamolvit, Vera Nilsén, Eduardo Gonzales, Claes-Göran Östenson, Annelie Brauner. Amaranthus caudatus extract inhibits the invasion of E. coli into uroepithelial cells. Journal of Ethnopharmacology. 2018; 220 ():155-158.
Chicago/Turabian StyleSoumitra Mohanty; Silvia Zambrana; Soizic Dieulouard; Witchuda Kamolvit; Vera Nilsén; Eduardo Gonzales; Claes-Göran Östenson; Annelie Brauner. 2018. "Amaranthus caudatus extract inhibits the invasion of E. coli into uroepithelial cells." Journal of Ethnopharmacology 220, no. : 155-158.
IntroductionType 2 diabetes (T2D) is increasingly contributing to the global burden of disease. Health systems in most parts of the world are struggling to diagnose and manage T2D, especially in low-income and middle-income countries, and among disadvantaged populations in high-income countries. The aim of this study is to determine the added benefit of community interventions onto health facility interventions, towards glycaemic control among persons with diabetes, and towards reduction in plasma glucose among persons with prediabetes.Methods and analysisAn adaptive implementation cluster randomised trial is being implemented in two rural districts in Uganda with three clusters per study arm, in an urban township in South Africa with one cluster per study arm, and in socially disadvantaged suburbs in Stockholm, Sweden with one cluster per study arm. Clusters are communities within the catchment areas of participating primary healthcare facilities. There are two study arms comprising a facility plus community interventions arm and a facility-only interventions arm. Uganda has a third arm comprising usual care. Intervention strategies focus on organisation of care, linkage between health facility and the community, and strengthening patient role in self-management, community mobilisation and a supportive environment. Among T2D participants, the primary outcome is controlled plasma glucose; whereas among prediabetes participants the primary outcome is reduction in plasma glucose.Ethics and disseminationThe study has received approval in Uganda from the Higher Degrees, Research and Ethics Committee of Makerere University School of Public Health and from the Uganda National Council for Science and Technology; in South Africa from the Biomedical Science Research Ethics Committee of the University of the Western Cape; and in Sweden from the Regional Ethical Board in Stockholm. Findings will be disseminated through peer-reviewed publications and scientific meetings.Trial registration numberISRCTN11913581; Pre-results.
David Guwatudde; Pilvikki Absetz; Peter Delobelle; Claes-Göran Östenson; Josefien Olmen Van; Helle Molsted Alvesson; Roy William Mayega; Elizabeth Ekirapa Kiracho; Juliet Kiguli; Carl Johan Sundberg; David Sanders; Göran Tomson; Thandi Puoane; Stefan Peterson; Meena Daivadanam. Study protocol for the SMART2D adaptive implementation trial: a cluster randomised trial comparing facility-only care with integrated facility and community care to improve type 2 diabetes outcomes in Uganda, South Africa and Sweden. BMJ Open 2018, 8, e019981 .
AMA StyleDavid Guwatudde, Pilvikki Absetz, Peter Delobelle, Claes-Göran Östenson, Josefien Olmen Van, Helle Molsted Alvesson, Roy William Mayega, Elizabeth Ekirapa Kiracho, Juliet Kiguli, Carl Johan Sundberg, David Sanders, Göran Tomson, Thandi Puoane, Stefan Peterson, Meena Daivadanam. Study protocol for the SMART2D adaptive implementation trial: a cluster randomised trial comparing facility-only care with integrated facility and community care to improve type 2 diabetes outcomes in Uganda, South Africa and Sweden. BMJ Open. 2018; 8 (3):e019981.
Chicago/Turabian StyleDavid Guwatudde; Pilvikki Absetz; Peter Delobelle; Claes-Göran Östenson; Josefien Olmen Van; Helle Molsted Alvesson; Roy William Mayega; Elizabeth Ekirapa Kiracho; Juliet Kiguli; Carl Johan Sundberg; David Sanders; Göran Tomson; Thandi Puoane; Stefan Peterson; Meena Daivadanam. 2018. "Study protocol for the SMART2D adaptive implementation trial: a cluster randomised trial comparing facility-only care with integrated facility and community care to improve type 2 diabetes outcomes in Uganda, South Africa and Sweden." BMJ Open 8, no. 3: e019981.
Diabetes Mellitus Type 2 prevalence is increasing worldwide; thus efforts to develop novel therapeutic strategies are required. Amaranthus caudatus (AC) is a pseudo-cereal with reported anti-diabetic effects that is usually consumed in food preparations in Bolivia. This study evaluated the anti-diabetic nutraceutical property of an AC hydroethanolic extract that contains mainly sugars and traces of polyphenols and amino acids (as shown by nalysis with liquid chromatography-mass spectrometry (LC-MS) and nuclear magnetic resonance (NMR)), in type 2 diabetic Goto-Kakizaki (GK) rats and healthy Wistar (W) rats. A single oral administration of AC extract (2000 mg/kg body weight) improved glucose tolerance during Oral Glucose Tolerance Tests (OGTT) in both GK rats and in W rats. Long-term treatment (21 days) with AC (1000 mg/kg b.w.) improved the glucose tolerance evaluated by the area under the curve (AUC) of glucose levels during the OGTT, in both GK and W rats. The HbA1c levels were reduced in both GK (19.83%) and W rats (10.7%). This effect was secondary to an increase in serum insulin levels in both GK and W rats and confirmed in pancreatic islets, isolated from treated animals, where the chronic AC exposure increased the insulin production 4.1-fold in GK and 3.7-fold in W rat islets. Furthermore, the effect of AC on in vitro glucose-dependent insulin secretion (16.7 mM glucose) was concentration-dependent up to 50 mg/mL, with 8.5-fold increase in GK and 5.7-fold in W rat islets, and the insulin secretion in perifused GK and W rat islets increased 31 and nine times, respectively. The mechanism of action of AC on insulin secretion was shown to involve calcium, PKA and PKC activation, and G-protein coupled-exocytosis since the AC effect was reduced 38% by nifedipine (L-type channel inhibitor), 77% by H89 (PKA inhibitor), 79% by Calphostine-C (PKC inhibitor) and 20% by pertussis toxin (G-protein suppressor).
Silvia Zambrana; Lena C. E. Lundqvist; Virginia Veliz; Sergiu-Bogdan Catrina; Eduardo Gonzales; Claes-Göran Östenson. Amaranthus caudatus Stimulates Insulin Secretion in Goto-Kakizaki Rats, a Model of Diabetes Mellitus Type 2. Nutrients 2018, 10, 94 .
AMA StyleSilvia Zambrana, Lena C. E. Lundqvist, Virginia Veliz, Sergiu-Bogdan Catrina, Eduardo Gonzales, Claes-Göran Östenson. Amaranthus caudatus Stimulates Insulin Secretion in Goto-Kakizaki Rats, a Model of Diabetes Mellitus Type 2. Nutrients. 2018; 10 (1):94.
Chicago/Turabian StyleSilvia Zambrana; Lena C. E. Lundqvist; Virginia Veliz; Sergiu-Bogdan Catrina; Eduardo Gonzales; Claes-Göran Östenson. 2018. "Amaranthus caudatus Stimulates Insulin Secretion in Goto-Kakizaki Rats, a Model of Diabetes Mellitus Type 2." Nutrients 10, no. 1: 94.
Physical activity can decrease the risk of complications related to diabetes type 2. Feasible and scalable strategies to implement support for a healthy lifestyle for patients in primary care are needed. The aim of the DiaCert-study is to evaluate a digital healthcare platform and the effect of a 12-week long smartphone-app physical activity intervention aiming at increasing physical activity (primary outcome) and improve levels of HbA1c (glycated hemoglobin), blood lipids, blood pressure, body composition, as well as other lifestyle factors and overall health in patients with diabetes type 2. The DiaCert-study is a two-arm, randomized controlled trial that will include 250 patients with diabetes type 2. At baseline, participants are randomized 1:1 to intervention, i.e. use of the smartphone-app, during 12 weeks, or to a control group receiving only standard care. Physical activity and sedentary behavior, is objectively measured using the Actigraph GT3X. Biomarkers including HbA1c and blood lipids are measured in fasting blood samples. Anthropometrics include height, weight, waist circumference and body composition, and a number of lifestyle factors including sleep, diet, self-efficacy, and quality of life, are assessed through an extensive questionnaire. Measurements are made at baseline and at follow-up after 3, 6 and 12 months. Using new technology, is one way to bridge the gap between what patients need and what health care can offer. This study evaluates a new digital health care platform and will show if use of a smartphone-app to promote daily steps is an effective and feasible method to increase physical activity and improve clinical markers in patients with diabetes type 2. ClinicalTrials.gov Identifier: NCT03053336 ; 7 Feb, 2017.
Stephanie E. Bonn; Christina Alexandrou; Kristin Hjörleifsdottir Steiner; Klara Wiklander; Claes-Göran Östenson; Marie Löf; Ylva Trolle Lagerros. App-technology to increase physical activity among patients with diabetes type 2 - the DiaCert-study, a randomized controlled trial. BMC Public Health 2018, 18, 119 .
AMA StyleStephanie E. Bonn, Christina Alexandrou, Kristin Hjörleifsdottir Steiner, Klara Wiklander, Claes-Göran Östenson, Marie Löf, Ylva Trolle Lagerros. App-technology to increase physical activity among patients with diabetes type 2 - the DiaCert-study, a randomized controlled trial. BMC Public Health. 2018; 18 (1):119.
Chicago/Turabian StyleStephanie E. Bonn; Christina Alexandrou; Kristin Hjörleifsdottir Steiner; Klara Wiklander; Claes-Göran Östenson; Marie Löf; Ylva Trolle Lagerros. 2018. "App-technology to increase physical activity among patients with diabetes type 2 - the DiaCert-study, a randomized controlled trial." BMC Public Health 18, no. 1: 119.
Objectives: The development of microvascular complications in diabetes is a complex process in which endothelial dysfunction is of importance. Emerging evidence suggests that arginase is a key mediator of endothelial dysfunction in type 2 diabetes mellitus by reciprocally regulating nitric oxide bioavailability. The aim of this prospective intervention study was to test the hypothesis that arginase activity is increased and that arginase inhibition improves microvascular endothelial function in patients with type 2 diabetes and microvascular dysfunction. Design: Microvascular endothelium-dependent and -independent dilatation were determined in patients with type 2 diabetes (n=12) and healthy age-matched control subjects (n=12) with laser Doppler flowmetry during iontophoretic application of acetylcholine and sodium nitroprusside, respectively, before and after administration of the arginase inhibitor Nω-hydroxy-nor-L-arginine (nor-NOHA, 120 min). Plasma ratios of amino acids involved in arginase and nitric oxide synthase activities were determined. The laser Doppler flowmetry data was the primary outcome variable. Results: Microvascular endothelium-dependent dilatation was impaired in subjects with type 2 diabetes (p<0.05). After administration of nor-NOHA microvascular endothelial function improved significantly in patients with type 2 diabetes to the level observed in healthy controls. Endothelium-independent vasodilatation did not change significantly. Subjects with type 2 diabetes had higher levels of ornithine and higher ratios of ornithine/citrulline and ornithine/arginine (p<0.05), suggesting increased arginase activity. Conclusion: Arginase inhibition improves microvascular endothelial function in patients with type 2 diabetes and microvascular dysfunction. Arginase inhibition may represent a novel therapeutic strategy to improve microvascular endothelial function in patients with type 2 diabetes.
Oskar Kövamees; Alexey Shemyakin; Antonio Checa; Craig E. Wheelock; Jon O Lundberg; Claes-Göran Östenson; John Pernow. Arginase inhibition improves microvascular endothelial function in patients with type 2 diabetes mellitus. The Journal of Clinical Endocrinology & Metabolism 2016, 101, 3952 -3958.
AMA StyleOskar Kövamees, Alexey Shemyakin, Antonio Checa, Craig E. Wheelock, Jon O Lundberg, Claes-Göran Östenson, John Pernow. Arginase inhibition improves microvascular endothelial function in patients with type 2 diabetes mellitus. The Journal of Clinical Endocrinology & Metabolism. 2016; 101 (11):3952-3958.
Chicago/Turabian StyleOskar Kövamees; Alexey Shemyakin; Antonio Checa; Craig E. Wheelock; Jon O Lundberg; Claes-Göran Östenson; John Pernow. 2016. "Arginase inhibition improves microvascular endothelial function in patients with type 2 diabetes mellitus." The Journal of Clinical Endocrinology & Metabolism 101, no. 11: 3952-3958.
Bipolar patients are at a higher risk of developing metabolic disorders. Cardiovascular morbidity and mortality is twice the rate reported in the population. Antipsychotic medication increases the risk of metabolic abnormalities. However, bipolar disorder and schizophrenia have a similarly increased mortality from cardiovascular causes of death, although bipolar patients medicate with antipsychotic drugs to a much smaller extent than schizophrenic patients. Bipolar disorder and schizophrenia share substantial genetic risk components; thus, increased metabolic abnormalities is hypothesized to be an effect of specific sets of metabolic risk genes, which might overlap with the metabolic risk genes in schizophrenia. This study reports that a functional genetic variant of MTNR1B, previously implicated in the impairment of glucose-stimulated insulin release also in schizophrenia, was associated with elevated fasting glucose levels in bipolar patients and controls. This finding suggests that the MTNR1B-dependent vulnerability for elevated fasting plasma glucose levels is shared between bipolar disorder and schizophrenia.
Dzana S. Hukic; Catharina Lavebratt; Louise Frisén; Lena Backlund; Agneta Hilding; Harvest F. Gu; Claes-Göran Östenson; David Erlinge; Ewa Ehrenborg; Martin Schalling; Urban Ösby. Melatonin receptor 1B gene associated with hyperglycemia in bipolar disorder. Psychiatric Genetics 2016, 26, 136 -139.
AMA StyleDzana S. Hukic, Catharina Lavebratt, Louise Frisén, Lena Backlund, Agneta Hilding, Harvest F. Gu, Claes-Göran Östenson, David Erlinge, Ewa Ehrenborg, Martin Schalling, Urban Ösby. Melatonin receptor 1B gene associated with hyperglycemia in bipolar disorder. Psychiatric Genetics. 2016; 26 (3):136-139.
Chicago/Turabian StyleDzana S. Hukic; Catharina Lavebratt; Louise Frisén; Lena Backlund; Agneta Hilding; Harvest F. Gu; Claes-Göran Östenson; David Erlinge; Ewa Ehrenborg; Martin Schalling; Urban Ösby. 2016. "Melatonin receptor 1B gene associated with hyperglycemia in bipolar disorder." Psychiatric Genetics 26, no. 3: 136-139.
Vanadium compounds have been explored as therapy of diabetes, and most studies have focussed on insulin mimetic effects, i.e. reducing hyperglycemia by improving glucose sensitivity and thus glucose uptake in sensitive tissues. We have recently shown that bis(1,2-dimethyl-3-hydroxy-4-pyridinonato)oxidovanadium(IV), VO(dmpp)2, has promising effects when compared to another vanadium compound, bis(maltolato)oxidovanadium(IV), BMOV, and insulin itself, in isolated adipocytes and in vivo in Goto-Kakizaki (GK) rats, an animal model of hereditary type 2 diabetes (T2D).We now have investigated in GK rats whether VO(dmpp)2 also modulates another important defect in T2D, impaired insulin secretion. VO(dmpp)2, but not BMOV, stimulated insulin secretion from isolated GK rat pancreatic islets at high, 16.7mM, but not at low–normal, 3.3 mM, glucose concentration. Mechanistic studies demonstrate that the insulin releasing effect of VO(dmpp)2 is due to its interaction with several steps in the stimulus-secretion coupling for glucose, including islet glucose metabolism and K-ATP channels, L-type Ca2+ channels, modulation by protein kinases A and C, as well as the exocytotic machinery. In conclusion, VO(dmpp)2 exhibits properties of interest for treatment of the insulin secretory defect in T2D, in addition to its well-described insulin mimetic activity.
Julien Pelletier; Neuza Domingues; M.Margarida C.A. Castro; Claes-Göran Östenson. In vitro effects of bis(1,2-dimethyl-3-hydroxy-4-pyridinonato)oxidovanadium(IV), or VO(dmpp)2, on insulin secretion in pancreatic islets of type 2 diabetic Goto-Kakizaki rats. Journal of Inorganic Biochemistry 2016, 154, 29 -34.
AMA StyleJulien Pelletier, Neuza Domingues, M.Margarida C.A. Castro, Claes-Göran Östenson. In vitro effects of bis(1,2-dimethyl-3-hydroxy-4-pyridinonato)oxidovanadium(IV), or VO(dmpp)2, on insulin secretion in pancreatic islets of type 2 diabetic Goto-Kakizaki rats. Journal of Inorganic Biochemistry. 2016; 154 ():29-34.
Chicago/Turabian StyleJulien Pelletier; Neuza Domingues; M.Margarida C.A. Castro; Claes-Göran Östenson. 2016. "In vitro effects of bis(1,2-dimethyl-3-hydroxy-4-pyridinonato)oxidovanadium(IV), or VO(dmpp)2, on insulin secretion in pancreatic islets of type 2 diabetic Goto-Kakizaki rats." Journal of Inorganic Biochemistry 154, no. : 29-34.
Protein kinase C (PKC) is a family of protein kinases controlling protein phosphorylation and playing important roles in the regulation of metabolism. We have investigated expression levels of PKC isoforms in pancreatic islets and liver of diabetic Goto-Kakizaki (GK) rats with and without insulin treatment to evaluate their association with glucose homeostasis. mRNA and protein expression levels of PKC isoforms were assessed in pancreatic islets and liver of Wistar rats and GK rats with or without insulin treatment. PKCα and PKCζ mRNA expressions were down-regulated in islets of GK compared with Wistar rats. PKCα and phosphorylated PKCα (p-PKCα) protein expressions were decreased in islets of GK compared with insulin-treated GK and Wistar rats. PKCζ protein expression in islets was reduced in GK and insulin-treated GK compared with Wistar rats, but p-PKCζ was decreased only in GK rats. Islet PKCε mRNA and protein expressions were lower in GK compared with insulin-treated GK and Wistar rats. In liver, PKCδ and PKCζ mRNA expressions were decreased in both GK and insulin-treated GK compared with Wistar rats. Hepatic PKCζ protein expression was diminished in both GK rats with and without insulin treatment compared with Wistar rats. Hepatic PKCε mRNA expression was down-regulated in insulin-treated GK compared with GK and Wistar rats. PKCα, PKCε, and p-PKCζ expressions were secondary to hyperglycaemia in GK rat islets. Hepatic PKCδ and PKCζ mRNA expressions were primarily linked to hyperglycaemia. Additionally, hepatic PKCε mRNA expression could be under control of insulin.
Mohammed Seed Ahmed; Julien Pelletier; Hannes Leumann; Harvest F. Gu; Claes-Göran Östenson. Expression of Protein Kinase C Isoforms in Pancreatic Islets and Liver of Male Goto-Kakizaki Rats, a Model of Type 2 Diabetes. PLOS ONE 2015, 10, e0135781 .
AMA StyleMohammed Seed Ahmed, Julien Pelletier, Hannes Leumann, Harvest F. Gu, Claes-Göran Östenson. Expression of Protein Kinase C Isoforms in Pancreatic Islets and Liver of Male Goto-Kakizaki Rats, a Model of Type 2 Diabetes. PLOS ONE. 2015; 10 (9):e0135781.
Chicago/Turabian StyleMohammed Seed Ahmed; Julien Pelletier; Hannes Leumann; Harvest F. Gu; Claes-Göran Östenson. 2015. "Expression of Protein Kinase C Isoforms in Pancreatic Islets and Liver of Male Goto-Kakizaki Rats, a Model of Type 2 Diabetes." PLOS ONE 10, no. 9: e0135781.